Keywords: Illumina, Roche, M&A, Diagnostics

Illumina board says Roche hostile bid “grossly inadequate”

Article | 08 February 2012

Print This

Having thoroughly reviewed Swiss drug and diagnostics major Roche’s (ROG: SIX) hostile takeover bid, USA-based Illumina (Nasdaq: ILMN) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in